Zentalis Pharmaceuticals Inc. Company Profile
NASDAQ: ZNTLHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
After hours: 2.64 0.00%
Zentalis Pharmaceuticals at a glance
Zentalis Pharmaceuticals Inc. (NASDAQ: ZNTL) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in San Diego, CA. Zentalis Pharmaceuticals is led by Ms. Julie M. Eastland M.B.A. and employs about 106 people. The company's shares have traded publicly since 2020.
At a market capitalization of $259.0 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001725160, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Zentalis Pharmaceuticals do?
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is based in San Diego, California.
Business description based on the company's public filings.
Company information
- Legal name
- Zentalis Pharmaceuticals Inc.
- Ticker
- NASDAQ: ZNTL
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Ms. Julie M. Eastland M.B.A.
- Employees
- 106
- Headquarters
- 10275 Science Center Dr., San Diego, CA, United States
- Phone
- 858 263 4333
- Website
- zentalis.com
- IPO year
- 2020
- Market cap
- $259.04M
- SEC CIK
- 0001725160
Companies similar to Zentalis Pharmaceuticals
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| UPBUpstream Bio Inc. | 4.70 | +3.30% | $257.42M | vs ZNTL |
| VOGXVogenx Inc | 17.56 | +0.40% | $260.86M | vs ZNTL |
| IMRXImmuneering Corporation Class A | 3.94 | +5.35% | $254.91M | vs ZNTL |
| AMRNAmarin Corporation plc | 12.03 | +0.33% | $254.11M | vs ZNTL |
| VCREVicore Pharma Holding AB ADR | 9.00 | +2.04% | $253.48M | vs ZNTL |
| BBOTBridgeBio Oncology Therapeutics Inc. | 3.31 | -3.22% | $265.38M | vs ZNTL |
| ACIUAC Immune SA | 2.50 | -1.96% | $248.57M | vs ZNTL |
| QTTBQ32 Bio Inc. | 8.34 | +3.09% | $248.28M | vs ZNTL |